Xiong Ye, Huang Jianrong
The Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Chin Med. 2021 Aug 18;16(1):80. doi: 10.1186/s13020-021-00489-0.
Artemisinin and its derivatives belong to a family of drugs approved for the treatment of malaria with known clinical safety and efficacy. In addition to its anti-malarial effect, artemisinin displays anti-viral, anti-inflammatory, and anti-cancer effects in vivo and in vitro. Recently, much attention has been paid to the therapeutic role of artemisinin in liver diseases. Several studies suggest that artemisinin and its derivatives can protect the liver through different mechanisms, such as those pertaining to inflammation, proliferation, invasion, metastasis, and induction of apoptosis and autophagy. In this review, we provide a comprehensive discussion of the underlying molecular mechanisms and signaling pathways of artemisinin and its derivatives in treating liver diseases. Further pharmacological research will aid in determining whether artemisinin and its derivatives may serve as promising medicines for the treatment of liver diseases in the future.
青蒿素及其衍生物属于一类已获批准用于治疗疟疾的药物,具有已知的临床安全性和有效性。除抗疟疾作用外,青蒿素在体内和体外均表现出抗病毒、抗炎和抗癌作用。最近,青蒿素在肝脏疾病中的治疗作用受到了广泛关注。多项研究表明,青蒿素及其衍生物可通过不同机制保护肝脏,例如与炎症、增殖、侵袭、转移以及诱导凋亡和自噬相关的机制。在本综述中,我们全面讨论了青蒿素及其衍生物治疗肝脏疾病的潜在分子机制和信号通路。进一步的药理学研究将有助于确定青蒿素及其衍生物未来是否可能成为治疗肝脏疾病的有前景的药物。